OakChart

Mereo Biopharma Group Plc ADR

MREOHealthcare·Biotechnology·United Kingdom·Nano·NASD·Nov 11 • 3:59 PM ET

0.3066+0.0087 (2.92%)
2026-11-12 03:57 CET
Market cap
48.94 USD m
Revenue, TTM
0.80 USD m
Net income, TTM
-26.93 USD m
Free cash flow, TTM
-22.07 USD m
EPS diluted, TTM
-0.17
P/E
-
Compare

Price

MREO against its 20, 50 and 200-day averages
2050200beatmiss
0.250.500.751.001.2581.9M163.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MREOclose 0.3120-day 0.2950-day 0.31200-day 0.320.3152w low

87.0% under the 52-week high of 2.37 on 11 Dec 2025. 52-week low 0.20 on 29 Dec 2025. Last 15 sessions, 19.9% high to low

Volume 0.10× normal · the line is the 50-bar volume average

Profile

MREO
52-week range, 5% of the way up
0.202.37

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Employees39
IPOApr 24, 2019
Beta0.20
ATR, 14d0.02
Rel volume0.10
Insider own0.00%
Inst own34.75%

Snapshot

6 groups

Valuation

Index-
Market Cap48.94M
Enterprise Value23.42M
Income-26.93M
Sales0.80M
Book/sh0.15
Cash/sh0.16
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees39
IPOApr 24, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S61.17
P/B2.06
P/C1.88
P/FCF-
EV/EBITDA-
EV/Sales29.27
Quick Ratio5.22
Current Ratio5.22
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.17
EPS next Y-0.03
EPS next Q-0.02
EPS this Y-15.64%
EPS next Y55.29%
EPS next 5Y-7.07%
EPS past 3/5Y8.97% 38.96%
Sales past 3/5Y- -
EPS Y/Y TTM36.23%
Sales Y/Y TTM57.97%
EPS Q/Q16.51%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.38.65% -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own34.75%
Inst Trans-12.32%
ROA-64.74%
ROE-76.59%
ROIC-113.56%
Gross Margin-100.35%
Oper. Margin-3800.24%
Profit Margin-3367.41%
SMA204.43%
SMA50-0.54%
SMA200-5.02%
Trades-

Technical

Shs Outstand159.69M
Shs Float-
Short Float-
Short Ratio0.86
Short Interest3.35M
52W High2.37 -87.06%
52W Low0.20 53.30%
Volatility8.48% 7.65%
ATR (14)0.02
RSI (14)51.85
Beta0.20
Rel Volume0.10
Avg Volume3.91M
Volume390,918

Performance

Perf Week1.15%
Perf Month-4.19%
Perf Quarter-0.36%
Perf Half Y18.15%
Perf YTD-26.42%
Perf Year-83.60%
Perf 3Y-85.26%
Perf 5Y-86.61%
Perf 10Y-
Recom2.17
Target Price2.00
Prev Close0.30
Price0.31
Change %2.92%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Aug 19, 2026DowngradeJJP MorganNeutral → Underweight
Mar 23, 2026DowngradeJJP MorganOverweight → Neutral
Dec 30, 2025DowngradeJJefferiesBuy → Hold$0.50+63.1%
Mar 27, 2025InitiatedJJP MorganOverweight$7+2,183.1%
Dec 06, 2024InitiatedJJefferiesBuy$7+2,183.1%
Jun 13, 2024InitiatedRRobert W. BairdOutperform$8+2,509.3%
Oct 13, 2023ResumedBBTIG ResearchBuy$4+1,204.6%
Aug 12, 2022InitiatedCCantor FitzgeraldOverweight$4+1,204.6%
May 05, 2021InitiatedBBTIG ResearchBuy$10+3,161.6%
Apr 05, 2021InitiatedNNeedhamBuy$10+3,161.6%

Peers

Mkt cap
TickerCompanyMkt cap
RAREUltragenyx Pharmaceutical Inc1.70B
KRROKorro Bio Inc197.78M
KROSKeros Therapeutics Inc187.22M
ABEOAbeona Therapeutics Inc131.44M
LRMRLarimar Therapeutics Inc283.61M
WVEWave Life Sciences Inc674.52M
PLXProtalix BioTherapeutics Inc252.18M
ZVRAZevra Therapeutics Inc705.13M
RZLTRezolute Inc393.69M
AKTXAkari Therapeutics Plc ADR13.04M

News

latest 14 of 200
  • Mereo BioPharma Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat (Pharmaceutical Business Review)
  • Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights (GlobeNewswire) +12.15%
  • Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) (PR Newswire)
  • Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) (GlobeNewswire)
  • Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
  • Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire) -5.18%
  • Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights (GlobeNewswire)
  • LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION (PR Newswire) -6.21%
  • Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire)
  • LEVI & KORSINSKY, LLP: CEO AND CSO NAMED AS CONTROL PERSON DEFENDANTS IN MEREO BIOPHARMA SECURITIES ACTION (PR Newswire)
  • LEVI & KORSINSKY, LLP: MEREO BIOPHARMA SECURITIES FILINGS ALLEGEDLY CONTAINED MISLEADING CLINICAL TRIAL DISCLOSURES (PR Newswire)
  • Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately (PR Newswire)
  • Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO (PR Newswire) -8.60%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.010-0.016-0.0100.800.005
2026Q22026-08-11-0.010-0.008-0.0440.003.505
2026Q12026-05-12-0.010-0.009-0.0420.0011.676
2025Q42026-03-19-0.023-0.013-0.0460.0023.337
2025Q32025-11-10-0.010-0.006-0.0440.2011.677
2025Q22025-08-12-0.020-0.012-0.0930.500.006
2025Q12025-05-13-0.020-0.007-0.0830.0026.887
2024Q42025-03-26-0.010-0.013-0.0450.0036.257
2024Q32024-11-12-0.020-0.018-0.0980.000.005
2024Q22024-08-13-0.020-0.010-0.0860.000.005
2024Q12024-05-15-0.010--0.0640.00--
2023Q42024-03-27-0.020-0.020---1
2023Q22023-09-07-0.020-0.020---1
2022S22023-03-28-0.029--0.0370.00-1
2022S12022-11-18-0.139--0.0340.00-1
2021S22022-06-15-0.033--0.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.451-2.984-2.4860.000.00
2020FY-3.311--3.1070.00-
2021FY-0.066-0.0630.15048.0124.86
2022FY-0.074-0.080-0.3490.000.00
2023FY-0.040-0.044-0.20110.008.57
2024FY-0.060-0.061-0.2930.0018.13
2025FY-0.050-0.056-0.0500.506.27
2026FY--0.058--0.64
2027FY--0.026--13.33
2028FY--0.061--9.15
2029FY--0.060--11.30
2030FY-0.000--85.90

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-092000.000.000.00
2026Q4S2026-10-092000.000.000.00
2026Q4S2026-08-202010.000.000.00
2026Q4S2026-08-173010.030.000.10
2026Q4S2026-08-112000.050.000.10
2026Q4S2026-06-272000.050.000.10
2026Q4S2026-06-0230016.700.0050.00
2026Q4S2026-05-1230116.700.0050.00
2026Q4S2026-04-0830116.700.0050.00
2026Q4S2026-03-1940112.540.0050.00
2026Q4S2026-03-143003.390.0010.10
2026Q4S2025-12-293023.390.0010.10
2026Q4S2025-11-1130026.370.0041.02
2026Q4S2025-11-1030026.370.0041.02

Estimate history

EPS, annual-3.606-3.001-2.486-3.1070.15-0.349-0.201-0.293-0.263-0.1681
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.098-0.045-0.083-0.093-0.044-0.046-0.042-0.044-0.036
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000050.149010.03900.5010.8
Period201720182019202020212022202320242025TTM
Sales, quarterly0000.50600000.8
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual14.21914.21519.34467.543116.734124.738140.059155.146159.132159.691
Period201720182019202020212022202320242025MRQ
Shares, quarterly154.734155.146159159159.097159.132159.616159.619159.691
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.800.500.0010.040.0050.150.000.000.00
Cost of Goods Sold Incl. D&A1.601.281.093.65-0.2625.512.052.010.05
Gross Profit-0.80-0.78-1.096.390.2624.64-2.05-2.01-0.05
Selling, General and Administrative Excl. Other29.5839.7246.3034.9253.9253.4346.1348.4046.89
Research and Development12.8317.8120.9417.4930.7532.4020.9630.1230.27
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-30.39-40.50-47.38-28.53-53.67-28.79-48.18-50.41-46.95
Interest Expense0.020.261.372.893.585.227.985.883.48
Unusual Expense-0.31-0.810.42-0.25-9.06-54.76141.072.03-0.36
Net Income Before Taxes-27.71-43.83-44.92-31.40-44.4619.59-213.45-52.46-49.74
Income Taxes-0.78-1.85-1.65-1.82-2.342.08-3.62-8.00-7.04
Consolidated Net Income-26.93-41.98-43.27-29.58-42.1217.50-209.83-44.45-42.71
Net Income From Continuing Operations-26.93-41.98-43.27-29.58-42.1217.50-209.83-44.45-42.71
Net Income-26.93-41.98-43.27-29.58-42.1217.50-209.83-44.45-42.71
EPS (Recurring)-0.17-0.27-0.29-0.23-0.40-0.18-1.64-2.41-3.02
EPS (Basic, Before Extraordinaries)-0.17-0.26-0.29-0.20-0.350.15-3.11-2.49-3.00
EPS (Diluted)-0.17-0.26-0.29-0.20-0.350.15-3.11-2.49-3.00
EBITDA-28.78-39.35-46.30-27.46-52.77-27.91-46.13-48.40-46.89
Non-Operating Income (Expense)2.39-3.884.25-0.233.73-1.16-16.225.860.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.407.627.393.713.853.681.621.692.36
Price To Earnings Ratio-----9.03---
Price To Sales Ratio80.90132.55-30.35-3.72---
Gross Margin-100.35-156.40-63.65-49.13---
Operating Margin-3,800.24-8,081.41--284.16--57.42---
Net Margin-3,367.41-8,375.61--294.66-34.90---
Shares Outstanding159.69159.13155.15140.06124.74116.7367.5419.3414.22
Market Capitalization48.9448.94541.57296.5993.74173.85241.6380.3360.73

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.800.000.000.000.000.510.000.00
Cost of Goods Sold Incl. D&A0.410.300.300.590.000.440.270.27
Gross Profit0.39-0.30-0.30-0.590.000.07-0.27-0.27
Selling, General and Administrative Excl. Other6.616.748.457.7910.2510.7010.9714.86
Research and Development2.091.814.744.194.245.443.958.74
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.21-7.04-8.75-8.38-10.25-10.63-11.25-15.13
Interest Expense0.000.000.000.020.030.020.180.37
Unusual Expense0.00-0.01-0.02-0.29-0.190.10-0.42-0.16
Net Income Before Taxes-5.96-7.14-6.80-7.81-7.42-15.55-13.12-7.55
Income Taxes-0.10-0.12-0.09-0.47-0.44-0.75-0.19-0.57
Consolidated Net Income-5.86-7.02-6.71-7.34-6.98-14.80-12.94-6.98
Net Income From Continuing Operations-5.86-7.02-6.71-7.34-6.98-14.80-12.94-6.98
Net Income-5.86-7.02-6.71-7.34-6.98-14.80-12.94-6.98
EPS (Recurring)-0.04-0.04-0.04-0.05-0.04-0.09-0.08-0.05
EPS (Basic, Before Extraordinaries)-0.04-0.04-0.04-0.05-0.04-0.09-0.08-0.04
EPS (Diluted)-0.04-0.04-0.04-0.05-0.04-0.09-0.08-0.04
EBITDA-5.81-6.74-8.45-7.79-10.26-10.33-10.97-14.86
Non-Operating Income (Expense)0.26-0.101.930.292.66-4.80-2.117.80
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.831.181.472.931.441.641.661.50
Price To Sales Ratio80.90-104.54131.00651.10855.99--
Gross Margin49.13----14.00--
Operating Margin-777.25-----2,099.80--
Net Margin-732.87-----2,923.20--
Shares Outstanding159.69159.62159.62159.13159.10159.00159.00155.15
Market Capitalization48.9450.7152.5166.30327.54430.89349.08541.57

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments40.9969.8057.4267.76127.7232.0821.6635.0871.08
Short Term Receivables1.983.253.733.213.026.3415.877.5011.72
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.051.712.613.763.792.212.801.362.67
Total Current Assets45.0274.7663.7674.74134.5340.6340.3243.9385.46
Net Property, Plant & Equipment0.380.981.652.203.432.1515.310.190.21
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.520.641.0929.0133.2743.2658.8941.5644.65
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets45.9276.3966.50105.95171.2386.05114.5285.68130.32
Short Term Debt Incl. Current Port. of LT Debt0.206.240.6513.890.840.8723.488.712.62
Accounts Payable1.332.442.350.000.000.000.000.000.00
Income Tax Payable---0.002.06----
Other Current Liabilities2.775.176.4915.7914.0810.8416.1011.8910.39
Total Current Liabilities4.3013.859.4929.6816.9911.7139.5820.6013.01
Long Term Debt0.000.195.301.4721.8623.6519.5118.6525.87
Provision for Risks Charges0.000.000.000.001.791.661.923.365.51
Other Liabilities0.701.391.180.3711.4069.490.191.321.82
Total Liabilities5.0015.4215.9631.5352.03106.5161.1943.9546.21
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity40.9260.9750.5474.42119.19-20.4653.3341.7484.11
Total Shareholders Equity40.9260.9750.5474.42119.19-20.4653.3341.7484.11
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity40.9260.9750.5474.42119.19-20.4653.3341.7484.11
Total Liabilities & Stockholders Equity45.9276.3966.50105.95171.2386.05114.5285.68130.32
Book Value Per Share0.260.390.360.601.02-0.302.762.945.92
Tangible Book Value Per Share0.250.390.350.360.74-0.94-0.290.012.78
Full-Time Employees393633364538463731
Price to Book Ratio2.067.473.871.041.57-11.821.190.64-
Return on Assets-68.64-60.57-34.31-30.3913.60-209.23-44.41-39.54-42.07
Return on Equity-82.40-77.61-47.34-43.5135.45-1,276.93-93.52-67.87-54.90
Return on Invested Capital-102.59-70.76-52.98-55.5012.41-6,590.88-61.03-70.72-45.43
Quick Ratio10.465.406.722.527.923.471.022.136.57
Current Ratio10.465.406.722.527.923.471.022.136.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-26.90-41.98-43.27-29.58-44.4619.59-213.45-52.46-49.74
Depreciation1.601.151.091.070.900.882.052.010.05
Other Funds (Non Cash)3.7912.999.708.90-5.64-25.14175.76-0.1113.82
Funds from Operations-21.51-27.83-32.48-19.61-49.20-4.67-35.63-50.55-35.88
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.56-3.21-0.37-1.602.24-2.54-4.37-9.783.21
Cash from Operating Activities-22.07-31.04-32.85-21.21-46.96-7.20-40.01-60.33-32.66
Capital Expenditures-0.30-0.32-0.70-0.42-0.01-0.74-0.02-0.03-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00-0.450.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.0012.850.00
Purchase or Sale of Investments0.000.000.000.000.000.000.0041.930.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.0041.930.00
Other Uses0.000.000.000.00-0.830.000.000.000.00
Other Sources-0.000.300.000.001.830.162.340.000.00
Cash from Investing Activities-0.30-0.02-0.70-0.420.99-0.581.8654.75-0.04
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.040.3346.1711.140.00107.7524.15-1.27-0.06
Repurchase of Common Pref Stock0.000.000.00-0.510.000.000.00-1.27-0.41
Sale of Common Pref Stock0.040.3346.1711.650.00107.7524.150.000.35
Proceedsfrom Stock Options0.00-0.2046.1711.650.00107.6824.150.000.35
Issuance or Reduction of Debt, Net0.000.000.00-3.230.000.0026.790.00-0.62
Change in Long Term Debt0.000.000.00-3.230.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00-
Reduction of Long Term Debt0.000.000.00-3.230.000.000.000.00-
Net Financing Active Other Cash Flow0.000.000.000.100.190.000.00-0.970.10
Other Financing Activities Uses0.000.000.000.000.000.000.00-0.970.00
Cash from Financing Activities0.040.3346.178.00-0.97106.8048.26-5.07-0.57
Exchange Rate Effect-0.251.86-0.232.830.18-1.60-0.99-0.45-0.06
Net Change in Cash-22.59-28.8812.39-10.80-46.7697.419.13-11.09-33.34
Free Cash Flow-22.07-31.06-32.85-21.21-46.97-7.94-40.03-60.36-32.71
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments26.1030.1236.2240.9948.7056.12
Short Term Receivables0.611.921.881.981.533.75
Inventories0.000.000.000.000.000.00
Other Current Assets1.961.361.932.052.171.55
Total Current Assets28.6733.4040.0345.0252.4161.42
Net Property, Plant & Equipment0.781.060.200.380.550.74
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.130.260.380.520.640.47
Other Assets0.000.000.000.000.000.00
Total Assets29.5834.7140.6145.9253.6062.63
Short Term Debt Incl. Current Port. of LT Debt0.581.030.000.200.400.60
Accounts Payable1.001.123.231.330.881.14
Other Current Liabilities3.913.532.952.774.745.82
Total Current Liabilities5.495.686.184.306.027.56
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.380.390.380.700.990.90
Total Liabilities5.876.066.565.007.008.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity23.7128.6534.0540.9246.6054.18
Total Shareholders Equity23.7128.6534.0540.9246.6054.18
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity23.7128.6534.0540.9246.6054.18
Total Liabilities & Stockholders Equity29.5834.7140.6145.9253.6062.63
Book Value Per Share0.150.180.210.260.290.34
Tangible Book Value Per Share0.150.180.210.250.290.34
Full-Time Employees---39--
Price to Book Ratio2.061.491.281.426.057.17
Return on Assets-64.74-57.62-65.77-68.77-58.58-62.82
Return on Equity-76.59-67.72-76.11-82.55-70.00-75.09
Return on Invested Capital-24.71-24.49-19.70-17.94-14.98-27.31
Quick Ratio5.225.886.4810.468.718.13
Current Ratio5.225.886.4810.468.718.13

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.86-7.01-6.71-7.32-6.91-14.80
Depreciation0.410.300.300.59-0.010.30
Other Funds (Non Cash)0.881.66-0.061.31-0.747.60
Funds from Operations-4.57-5.05-6.46-5.42-7.66-6.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.52-0.992.16-2.250.41-0.85
Cash from Operating Activities-4.05-6.05-4.30-7.67-7.26-7.76
Capital Expenditures0.00-0.00-0.300.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.00-0.000.300.00
Cash from Investing Activities0.00-0.00-0.300.000.30-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.04-0.00-0.13
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.04-0.00-0.13
Proceedsfrom Stock Options0.000.000.000.000.00-0.14
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.04-0.00-0.13
Exchange Rate Effect0.03-0.06-0.16-0.07-0.431.44
Net Change in Cash-4.02-6.11-4.76-7.70-7.39-6.45
Free Cash Flow-4.05-6.05-4.30-7.67-7.26-7.76

Revenue breakdown

Pharmaceutical Preparations2025: 500.00K
United Kingdom2025: 500.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.10%3.3M159.6M3.94M
2026-10-152.02%3.2M159.6M4.00M
2026-09-301.68%2.7M159.6M4.03M
2026-09-151.93%3.1M159.6M4.01M
2026-08-312.36%3.8M159.6M4.29M
2026-08-142.70%4.3M159.6M5.80M
2026-07-31-3.4M-3.23M
2026-07-152.22%3.5M159.6M3.36M
2026-06-303.69%5.9M159.6M3.43M
2026-06-153.35%5.3M159.6M3.32M
2026-05-295.11%8.2M159.6M2.99M
2026-05-153.56%5.7M159.6M1.76M
2026-04-304.09%6.5M159.1M2.04M
2026-04-155.20%8.3M159.1M3.23M
2026-03-316.85%10.9M159.1M8.91M
2026-03-137.08%11.3M159.1M14.96M
2026-02-278.65%13.8M159.1M15.00M
2026-02-138.86%14.1M159.1M14.80M
2026-01-309.48%13.0M137.5M14.44M
2026-01-157.14%9.8M137.5M13.13M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.055.0362,1250.000.419-0.0050.000
call1.000.000.050.057.6872,7900.000.350-0.0070.000
call1.500.003.800.058.8253540.000.322-0.0090.000
call2.000.000.050.059.3192870.000.316-0.0080.000
call3.000.003.800.0510.69094.000.000.297-0.0100.000
put0.500.000.350.1711.1192.000.00-0.583-0.0050.000
put1.000.001.000.750.0001.001.00-0.655-0.0080.000
put1.500.003.801.300.0005.000.00-0.678-0.0080.000
put2.001.301.951.7523.5482.001.00-0.690-0.0090.000
put3.000.205.002.750.0003.001.00-0.703-0.0100.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-28SCHEDULE 13G/ASEC
2026-08-198-KCurrent report2026-08-18SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-14SCHEDULE 13GSEC
2026-05-128-K/A2026-05-12SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-09ARSAnnual report to security holders. 2025-12-31SEC
2026-04-09DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-08SEC
2026-03-27PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-03-27SEC
2026-03-278-KCurrent report2026-03-26SEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-274Statement of changes in beneficial ownership of securities2026-02-26SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-17SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Rubric Capital Management LP9.59%
683 Capital Management, LLC7.38%
BANK OF AMERICA CORP /DE/5.13%
Defilade Capital Management, L.P.4.74%
Newtyn Management, LLC1.88%
Tejara Capital Ltd1.26%
TWO SIGMA INVESTMENTS, LP0.83%
EcoR1 Capital, LLC0.63%
JANE STREET GROUP, LLC0.49%
Ishara Investments LP0.48%

Funds

Fund% owned
iShares Genomics Immunology and Healthcare ETF0.15%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF0.08%
Virtus Biotech Clinical Trials Etf0.08%
Fidelity Nasdaq Composite Index Fund0.06%
Blackstone Alternative Multi-Strategy Fund0.01%

OakChart. MREO. Cached 15 minutes.

Some panels did not load: insider.